Literature DB >> 7518840

Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts.

K Harada1, W Grossman, M Friedman, E R Edelman, P V Prasad, C S Keighley, W J Manning, F W Sellke, M Simons.   

Abstract

The effect of basic fibroblast growth factor (bFGF) administration on regional myocardial function and blood flow in chronically ischemic hearts was studied in 26 pigs instrumented with proximal circumflex coronary artery (LCX) ameroid constrictors. In 13 animals bFGF was administered extraluminally to the proximal left anterior descending (LAD) and LCX arteries with heparin-alginate beads and 13 other animal served as controls. bFGF-treated pigs showed a fourfold reduction in left ventricular infarct size compared to untreated controls (infarct size: 1.2 +/- 0.4% vs. 5.1 +/- 1.3% of LV mass, mean +/- SEM, P < 0.05). Percent fractional shortening (% FS) in the LCX area at rest was reduced compared with the LAD region in both bFGF and control pigs. However, there was better recovery in the LCX area after rapid pacing in bFGF-treated pigs (% FSLCX/% FSLAD, 22.9 +/- 7.3%-->30.5 +/- 8.5%, P < 0.05 vs. prepacing) than in controls (16.0 +/- 7.8%-->14.3 +/- 7.0%, P = NS). Furthermore, LV end-diastolic pressure rise with rapid pacing was less in bFGF-treated than control pigs (pre-pacing; pacing; post-pacing, 10 +/- 1; 17 +/- 3; 11 +/- 1* mmHg vs 10 +/- 1; 24 +/- 4; 15 +/- 1 mmHg, *P < 0.05 vs. control). Coronary blood flow in the LCX territory (normalized for LAD flow) was also better during pacing in bFGF-treated pigs than in controls. Thus, periadventitial administration of bFGF in a gradual coronary occlusion model in pigs results in improvement of coronary flow and reduction in infarct size in the compromised territory as well as in prevention of pacing-induced hemodynamic deterioration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518840      PMCID: PMC296139          DOI: 10.1172/JCI117378

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

Review 1.  Angiogenesis.

Authors:  J Folkman; Y Shing
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  Endothelial modulation of porcine coronary microcirculation perfused via immature collaterals.

Authors:  F W Sellke; Y Kagaya; R G Johnson; T Shafique; F J Schoen; W Grossman; R M Weintraub
Journal:  Am J Physiol       Date:  1992-06

Review 3.  Fibroblast growth factors: from genes to clinical applications.

Authors:  D Gospodarowicz
Journal:  Cell Biol Rev       Date:  1991

Review 4.  Angiogenesis in the adult heart.

Authors:  W Schaper
Journal:  Basic Res Cardiol       Date:  1991       Impact factor: 17.165

5.  Controlled and modulated release of basic fibroblast growth factor.

Authors:  E R Edelman; E Mathiowitz; R Langer; M Klagsbrun
Journal:  Biomaterials       Date:  1991-09       Impact factor: 12.479

6.  bFGF enhances the development of the collateral circulation after acute arterial occlusion.

Authors:  J O Chleboun; R N Martins; C A Mitchell; T V Chirila
Journal:  Biochem Biophys Res Commun       Date:  1992-06-15       Impact factor: 3.575

7.  Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor.

Authors:  R Baffour; J Berman; J L Garb; S W Rhee; J Kaufman; P Friedmann
Journal:  J Vasc Surg       Date:  1992-08       Impact factor: 4.268

8.  Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries.

Authors:  E R Edelman; M A Nugent; L T Smith; M J Karnovsky
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 9.  Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions.

Authors:  M Klagsbrun
Journal:  Semin Cancer Biol       Date:  1992-04       Impact factor: 15.707

10.  Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study.

Authors:  V Lindner; M A Reidy
Journal:  Circ Res       Date:  1993-09       Impact factor: 17.367

View more
  39 in total

1.  Therapeutic Angiogenesis for Coronary Artery Disease.

Authors:  Tanveer A. Khan; Frank W. Sellke; Roger J. Laham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

2.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart.

Authors:  H Su; R Lu; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 3.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 4.  Angiogenesis and vasculogenesis in treatment of cardiovascular disease.

Authors:  A Rivard; J M Isner
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

Review 5.  Angiogenesis and the heart: therapeutic implications.

Authors:  M D Hariawala; F W Sellke
Journal:  J R Soc Med       Date:  1997-06       Impact factor: 5.344

Review 6.  [Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease].

Authors:  S Rosenkranz; M Böhm; A Kazlauskas
Journal:  Med Klin (Munich)       Date:  1999-09-15

7.  Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model.

Authors:  Shao-ping Nie; Xiao Wang; Shi-bin Qiao; Qiu-tang Zeng; Ju-quan Jiang; Xiao-qing Liu; Xiang-ming Zhu; Guo-xiang Cao; Chang-sheng Ma
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

8.  Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function.

Authors:  Jitka A I Virag; Marsha L Rolle; Julia Reece; Sandrine Hardouin; Eric O Feigl; Charles E Murry
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

Review 9.  Pharmacotherapy for end-stage coronary artery disease.

Authors:  Neel R Sodha; Louis M Chu; Munir Boodhwani; Frank W Sellke
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

Review 10.  Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Authors:  Alejandro R Chade; Nicholas Stewart
Journal:  J Am Soc Hypertens       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.